Erythrocyte Membrane-Wrapped Magnetic Nanotherapeutic Agents for Reduction and Removal of Blood Cr(VI)

• Published in: ACS applied materials & interfaces 2020-06, Vol.12 (25), p.28014-28023
• Main Authors: Wang, Meng, Yan, Wenqiang, Chu, Meilin, Li, Ting, Liu, Zhiyong, Yu, Yueqi, Huang, Yangyang, Zhu, Tianyu, Wan, Mimi, Mao, Chun, Shi, Dongquan
• Format: Article
• Language: English
• Subjects: Animals; Biological and Medical Applications of Materials and Interfaces; Chromium - blood; Chromium - chemistry; Erythrocyte Membrane - chemistry; Heavy Metal Poisoning - blood; Heavy Metal Poisoning - therapy; Nanocomposites - chemistry; Porosity; Silicon Dioxide - chemistry; Swine
• ISSN: 1944-8244; 1944-8252
• DOI: 10.1021/acsami.0c06437

The hazard of hexavalent chromium (Cr­(VI)) from environmental pollution and medical implanted metal has been recognized widely. However, removal of trace amount of Cr­(VI) in the blood circumstance faces tremendous difficulties for that most of Cr­(VI) located in erythrocytes, thus there is almost no literature to report the removal of Cr­(VI) in blood. Herein, a removal strategy, named as reduction–adsorption–separation, is proposed to realize the removal of Cr­(VI) in blood. First, magnetic core–shell mesoporous nanocomposite is fabricated by using Fe3O4 nanoparticles as magnetic core and mesoporous silica (MS) as shell, hyperbranched polyamide (HPA) as mesoporous channel modifier and ascorbic acid (ASC) as the reductant drug loaded in the mesoporous channels, which is also denoted as Fe/MS/HPA/ASC. Then, on the basis of the bionic idea, the erythrocyte membrane (EM)-wrapped Fe/MS/HPA/ASC to protect ASC from deactivation is obtained and named as the therapeutic agent (Fe/MS/HPA/ASC@EM). During removal process, the therapeutic agent can enter in erythrocytes to use ASC to reduce Cr­(VI) to Cr­(III) and HPA in mesoporous channels to adsorb Cr­(III) and can then be recollected from blood by magnetic separation. Finally, an animal model of blood Cr­(VI) poisoning is constructed and used to test the removal ability of Cr­(VI) from pig blood in vivo, verifying the effectiveness of this blood Cr­(VI) removal strategy, providing a possible way to design more efficient and biosafe therapeutic agents for blood purification.